Abstract
1. Eight women with acute pyelonephritis were treated with i.v. enoxacin for 5 days. All were clinically cured and five had a bacteriological cure. Five women reported side effects. 2. During treatment there was no significant accumulation of enoxacin and the total clearance of the drug did not alter with repeated dosing. Drug elimination half-life (mean 4.3 h, s.d. 2.1) was similar to that reported in healthy volunteers. 3. Enoxacin should be compared with the aminoglycosides and beta-lactam antibiotics for the treatment of severe or complicated urinary tract infections.
MeSH Terms
Acute Disease
Adolescent
Adult
Anti-Infective Agents, Urinary/administration & dosage,pharmacology,therapeutic use
Enoxacin
Female
Humans
Injections, Intravenous
Middle Aged
Naphthyridines/administration & dosage,pharmacokinetics,therapeutic use
Pyelonephritis/drug therapy
Chemicals
Anti-Infective Agents, Urinary
Naphthyridines
Enoxacin
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Bailey R R
Department of Nephrology, Christchurch Hospital, New Zealand.
Walker R J
Lynn K L
Donaldson I M
Peddie B A
Dobbs B R
References (5)
5 references, click to expand
-
In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
Antimicrob Agents Chemother. 1983 May;23(5):641-8
PMID: 6575721
-
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.
Antimicrob Agents Chemother. 1983 May;23(5):658-63
PMID: 6223577
-
Enoxacin for the treatment of urinary tract infection.
N Z Med J. 1985 Apr 24;98(777):286-8
PMID: 3857511
-
In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.
Antimicrob Agents Chemother. 1983 Nov;24(5):754-63
PMID: 6229216
-
In vitro and in vivo antibacterial activity of AT-2266.
Antimicrob Agents Chemother. 1983 Jul;24(1):78-84
PMID: 6226242